LymphedemaV1, Main, Exploration, bibRecord, 006305

Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies

Identifieur interne : 006305 ( Main/Exploration ); précédent : 006304; suivant : 006306

Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies

Auteurs : Chloe Tesmoingt [France] ; Olivier Lidove [France] ; Axele Reberga [France] ; Marguerite Thetis [France] ; Chloe Ackaert [France] ; Pascale Nicaise [France] ; Philippe Arnaud [France] ; Thomas Papo [France]

Source :

British Journal of Clinical Pharmacology [ 0306-5251 ] ; 2009.

RBID : PMC:2791983

Abstract

AIMS

To report a severe adverse event related to enzyme replacement therapy with agalsidase in an hemizygous male patient treated for Fabry disease.

METHODS

Retrospective analysis of clinical, radiological and biochemical data in a patient who suffered adverse events related to both agalsidase alfa and agalsidase beta treatments.

RESULTS

A hemizygous male patient was first treated for Fabry disease with agalsidase alfa. After more than 1 year of therapy, infusion-related symptoms necessitated systemic steroids and antihistaminic therapy. Decline in kidney function prompted a switch for agalsidase beta. Anaphylactoid shock occurred after the second infusion. No serum IgE antibodies were disclosed. Skin-test reactivity to agalsidase beta was negative. Following a published rechallenge infusion protocol, agalsidase beta was reintroduced, leading to a second anaphylactoid shock episode. Enzyme replacement therapy was stopped and the patient was treated with symptomatic therapy only. This case was referred to the pharmacovigilance department.

CONCLUSION

The negativity of immunological tests (specific anti-agalsidase IgE antibodies and skin tests) does not rule out the risk of repeated anaphylactoid shock following agalsidase infusion.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791983

DOI: 10.1111/j.1365-2125.2009.03501.x
PubMed: 19917001
PubMed Central: 2791983

Affiliations:

France

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies</title>
<author><name sortKey="Tesmoingt, Chloe" sort="Tesmoingt, Chloe" uniqKey="Tesmoingt C" first="Chloe" last="Tesmoingt">Chloe Tesmoingt</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Clinical Pharmacy, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lidove, Olivier" sort="Lidove, Olivier" uniqKey="Lidove O" first="Olivier" last="Lidove">Olivier Lidove</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Internal Medicine, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Reberga, Axele" sort="Reberga, Axele" uniqKey="Reberga A" first="Axele" last="Reberga">Axele Reberga</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Clinical Pharmacy, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Thetis, Marguerite" sort="Thetis, Marguerite" uniqKey="Thetis M" first="Marguerite" last="Thetis">Marguerite Thetis</name>
<affiliation wicri:level="1"><nlm:aff id="au3"><institution>Department of Pneumology, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ackaert, Chloe" sort="Ackaert, Chloe" uniqKey="Ackaert C" first="Chloe" last="Ackaert">Chloe Ackaert</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Clinical Pharmacy, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nicaise, Pascale" sort="Nicaise, Pascale" uniqKey="Nicaise P" first="Pascale" last="Nicaise">Pascale Nicaise</name>
<affiliation wicri:level="1"><nlm:aff id="au4"><institution>Department of Immunology, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Arnaud, Philippe" sort="Arnaud, Philippe" uniqKey="Arnaud P" first="Philippe" last="Arnaud">Philippe Arnaud</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Clinical Pharmacy, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Papo, Thomas" sort="Papo, Thomas" uniqKey="Papo T" first="Thomas" last="Papo">Thomas Papo</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Internal Medicine, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">19917001</idno>
<idno type="pmc">2791983</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2791983</idno>
<idno type="RBID">PMC:2791983</idno>
<idno type="doi">10.1111/j.1365-2125.2009.03501.x</idno>
<date when="2009">2009</date>
<idno type="wicri:Area/Pmc/Corpus">002C88</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002C88</idno>
<idno type="wicri:Area/Pmc/Curation">002C87</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">002C87</idno>
<idno type="wicri:Area/Pmc/Checkpoint">003749</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">003749</idno>
<idno type="wicri:Area/Ncbi/Merge">003732</idno>
<idno type="wicri:Area/Ncbi/Curation">003732</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003732</idno>
<idno type="wicri:doubleKey">0306-5251:2009:Tesmoingt C:enzyme:therapy:in</idno>
<idno type="wicri:Area/Main/Merge">006381</idno>
<idno type="wicri:Area/Main/Curation">006305</idno>
<idno type="wicri:Area/Main/Exploration">006305</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies</title>
<author><name sortKey="Tesmoingt, Chloe" sort="Tesmoingt, Chloe" uniqKey="Tesmoingt C" first="Chloe" last="Tesmoingt">Chloe Tesmoingt</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Clinical Pharmacy, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lidove, Olivier" sort="Lidove, Olivier" uniqKey="Lidove O" first="Olivier" last="Lidove">Olivier Lidove</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Internal Medicine, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Reberga, Axele" sort="Reberga, Axele" uniqKey="Reberga A" first="Axele" last="Reberga">Axele Reberga</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Clinical Pharmacy, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Thetis, Marguerite" sort="Thetis, Marguerite" uniqKey="Thetis M" first="Marguerite" last="Thetis">Marguerite Thetis</name>
<affiliation wicri:level="1"><nlm:aff id="au3"><institution>Department of Pneumology, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ackaert, Chloe" sort="Ackaert, Chloe" uniqKey="Ackaert C" first="Chloe" last="Ackaert">Chloe Ackaert</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Clinical Pharmacy, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nicaise, Pascale" sort="Nicaise, Pascale" uniqKey="Nicaise P" first="Pascale" last="Nicaise">Pascale Nicaise</name>
<affiliation wicri:level="1"><nlm:aff id="au4"><institution>Department of Immunology, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Arnaud, Philippe" sort="Arnaud, Philippe" uniqKey="Arnaud P" first="Philippe" last="Arnaud">Philippe Arnaud</name>
<affiliation wicri:level="1"><nlm:aff id="au1"><institution>Department of Clinical Pharmacy, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Papo, Thomas" sort="Papo, Thomas" uniqKey="Papo T" first="Thomas" last="Papo">Thomas Papo</name>
<affiliation wicri:level="1"><nlm:aff id="au2"><institution>Department of Internal Medicine, Bichat-Claude Bernard University Hospital (AP-HP)</institution>
<addr-line>Paris, France</addr-line>
</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Paris</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">British Journal of Clinical Pharmacology</title>
<idno type="ISSN">0306-5251</idno>
<idno type="eISSN">1365-2125</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>AIMS</title>
<p>To report a severe adverse event related to enzyme replacement therapy with agalsidase in an hemizygous male patient treated for Fabry disease.</p>
</sec>
<sec><title>METHODS</title>
<p>Retrospective analysis of clinical, radiological and biochemical data in a patient who suffered adverse events related to both agalsidase alfa and agalsidase beta treatments.</p>
</sec>
<sec><title>RESULTS</title>
<p>A hemizygous male patient was first treated for Fabry disease with agalsidase alfa. After more than 1 year of therapy, infusion-related symptoms necessitated systemic steroids and antihistaminic therapy. Decline in kidney function prompted a switch for agalsidase beta. Anaphylactoid shock occurred after the second infusion. No serum IgE antibodies were disclosed. Skin-test reactivity to agalsidase beta was negative. Following a published rechallenge infusion protocol, agalsidase beta was reintroduced, leading to a second anaphylactoid shock episode. Enzyme replacement therapy was stopped and the patient was treated with symptomatic therapy only. This case was referred to the pharmacovigilance department.</p>
</sec>
<sec><title>CONCLUSION</title>
<p>The negativity of immunological tests (specific anti-agalsidase IgE antibodies and skin tests) does not rule out the risk of repeated anaphylactoid shock following agalsidase infusion.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
</list>
<tree><country name="France"><noRegion><name sortKey="Tesmoingt, Chloe" sort="Tesmoingt, Chloe" uniqKey="Tesmoingt C" first="Chloe" last="Tesmoingt">Chloe Tesmoingt</name>
</noRegion>
<name sortKey="Ackaert, Chloe" sort="Ackaert, Chloe" uniqKey="Ackaert C" first="Chloe" last="Ackaert">Chloe Ackaert</name>
<name sortKey="Arnaud, Philippe" sort="Arnaud, Philippe" uniqKey="Arnaud P" first="Philippe" last="Arnaud">Philippe Arnaud</name>
<name sortKey="Lidove, Olivier" sort="Lidove, Olivier" uniqKey="Lidove O" first="Olivier" last="Lidove">Olivier Lidove</name>
<name sortKey="Nicaise, Pascale" sort="Nicaise, Pascale" uniqKey="Nicaise P" first="Pascale" last="Nicaise">Pascale Nicaise</name>
<name sortKey="Papo, Thomas" sort="Papo, Thomas" uniqKey="Papo T" first="Thomas" last="Papo">Thomas Papo</name>
<name sortKey="Reberga, Axele" sort="Reberga, Axele" uniqKey="Reberga A" first="Axele" last="Reberga">Axele Reberga</name>
<name sortKey="Thetis, Marguerite" sort="Thetis, Marguerite" uniqKey="Thetis M" first="Marguerite" last="Thetis">Marguerite Thetis</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006305 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006305 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:2791983
   |texte=   Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:19917001" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

Serveur d'exploration sur le lymphœdème

Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies

Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.